Successful Treatment in Two Cases of Steroid-Dependent Cutaneous Polyarteritis nodosa with Low-Dose MethotrexateSchartz N.E.C.a · Alaoui S.a · Vignon-Pennamen M.D.a · Cordoliani F.a · Fermand J.P.b · Morel P.a · Rybojad M.a
Departments of aDermatology and bImmunohaematology, Hôpital Saint-Louis, Paris, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
To the best of our knowledge, only 3 cases of cutaneous polyarteritis nodosa (PAN) treated successfully with methotrexate (MTX) have been reported in the medical literature. We report 2 further cases of steroid-dependent cutaneous PAN treated successfully with low-dose weekly MTX therapy. The clinical and biological tolerance of MTX was excellent. The cutaneous lesions started to regress within 3 weeks. One of the patients reported full recovery which lasted 2 years after stopping the therapy. So, MTX seems to be an interesting therapy in the treatment of PAN because of its relatively low toxicity, its simple use, its quick action and prolonged results after MTX has been stopped.
© 2001 S. Karger AG, Basel
- Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF: Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: Cutaneous polyarteritis nodosa and Behçet’s disease. J Am Acad Dermatol 1991;24:973–978.
- Brody M, Bohm I, Biwer E, Bauer R: Erfolgreiche Behandlung einer Panarteriitis nodosa mit Methotrexat: Low-dose-Therapie. Hautarzt 1994;45:476–479.
Tannenbaum H: Combined therapy with methotrexate and prednisone in polyarteritis nodosa. CMAJ 1980;123:893–894.
- Boehm I, Bauer R: Low-dose methotrexate controls a severe form of polyateritis nodosa. Arch Dermatol 2000;136:167–169.
Esper GJ, Johnson JS: Update on the treatment of Wegener’s granulomatosis. Bull Rheum Dis 1999;48:1–4.
- Deguchi Y, Shibata N, Kishimoto S: Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 1990;81:311–314.
- Coll-Vinent B, Cebrian M, Cid MC, Font C, Esparaza J, Juan M, Yague J, Urbano-Marquez A, Grau JM: Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 1998;41:435–444.
- Grunewald J, Halapi E, Wahlstrom J, Giscombe R, Nityanand S, Sanjeevi C, Lefvert AK. T-cell expansions with conserved T-cell receptor β chain motifs in the peripheral blood of HLA-DRB1*0401 positive patients with necrotizing vasculitis. Blood 1998;92:3737–3744.
- Cutolo M, Bisso A, Sulli A, Felli L, Brita M, Pizzorini C, Villaggio B: Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 2000;27:2551–2557.
- Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820–1830.
- Izeradjene K, Revillard JP, Genestier L: Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells. Int Immunol 2001;13:85–93.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.